
FDA issues second CRL for dasiglucagon to treat hypoglycemia in congenital hyperinsulinism
This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.



























